CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 150 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $740,013 | -98.4% | 26,890 | -98.0% | 0.00% | -97.3% |
Q2 2023 | $45,096,193 | -20.8% | 1,329,095 | -16.0% | 0.04% | -28.8% |
Q1 2023 | $56,923,600 | -17.9% | 1,582,090 | +1.7% | 0.05% | -25.7% |
Q4 2022 | $69,320,523 | +93.6% | 1,555,318 | +22.1% | 0.07% | +94.4% |
Q3 2022 | $35,813,000 | – | 1,274,021 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |